Skip to main content

Table 2 Provision of cancer care to breast cancer patients without distant metastasis by age

From: Provision of breast cancer care and survival in Germany – results from a population-based high resolution study from Saarland

Treatment Category Overall   15-69 years   > = 70 years  
   N % N % N %
Overall   4025   2691   1334  
Local treatment Available 3038 75.5 2078 77.2 960 72.0
  BCSa 316 10.4 187 9.0 129 13.4
  BCS + radiotherapya 1716 56.5 1342 64.6 374 39.0
  Mastectomya 558 18.4 262 12.6 296 30.8
  Mastectomy + radiotherapya 424 14.0 284 13.7 140 14.6
  No surgerya 24 0.8 3 0.1 21 2.2
Lymph node dissection Available 3043 75.6 2145 79.7 898 67.3
  ALNDa 1274 41.9 812 37.9 462 51.4
  SNDa 1139 37.4 849 39.6 290 32.3
  SND + ALNDa 525 17.3 432 20.1 93 10.4
  Nonea 47 1.5 7 0.3 40 4.5
Chemotherapyb Available 1571 86.2 1154 91.4 417 74.5
  Yesa 1215 77.3 1050 91.0 165 39.6
  Nonea 356 22.7 104 9.0 252 60.4
Antiestrogen treatmentc Available 2232 75.8 1556 80.0 676 67.6
  Yesa 2035 91.2 1433 92.1 602 89.1
  Nonea 197 8.8 123 7.9 73 10.9
Targeted therapyd Available 443 55.7 325 58.9 118 48.4
  Yesa 188 42.4 164 50.5 24 20.3
  Nonea 255 57.6 161 49.5 94 79.7
  1. Local treatment, lymph node dissection and adjuvant systemic treatment of female BRC patients without distant metastases (ICD-10: C50) from Saarland diagnosed between 2005 and 2009. BCS: breast conserving surgery; ALND: axillary lymph node dissection; SND: sentinel node dissection; a) proportions among patients with available information; b) among patients with positive lymph nodes or hormone receptor negative tumors; c) among patients with hormone receptor positive or mixed tumors; d) among patients with HER2/neu expressed tumors; patients presenting with distant metastases or DCO notified tumors were excluded.
\